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Abstract. Harini M, Astirin OP. 2009. Blood cholesterol levels of hypercholesterolemic rat (Rattus norvegicus) after VCO treatment. 
Nusantara Bioscience 1: 53-58. This study aims to determine treatment effect of VCO on blood cholesterol levels  in 
hypercholesterolemic white rat (Rattus norvegicus L.). This study used 25 male rats of Wistar strain divided into five treatment groups, 
namely: control, simvastatin (1.3 mL/270 g BW), cholesterol (9:1 lard), VCO 1 (1 mL/270 g BW), and VCO 2 (1.3 mL/270 g BW). 
Treatment was given orally. Total cholesterol, LDL and HDL cholesterol levels were measured at day 1, day 14 and day 28. Cholesterol 
data (total cholesterol, LDL and HDL) were analyzed by Ancova and followed by contrast test at significance level of 5%.. The results 
showed that treatment of VCO at different doses significantly affected the decrease in blood total cholesterol, blood LDL levels, 
increasing blood HDL in hipercholesterolemic white rat.  
Key words: cholesterol, atherosclerosis, VCO.  
Abstrak. Harini M, Astirin OP. 2009. Kadar kolesterol darah tikus putih (Rattus norvegicus) hiperkolesterolemik setelah perlakuan 
VCO. Nusantara Bioscience 1: 53-58. Penelitian ini bertujuan untuk mengetahui pengaruh perlakuan VCO terhadap kadar kolesterol 
darah tikus putih (Rattus norvegicus L.) hiperkolesterolemik. Penelitian ini menggunakan 25 tikus putih jantan galur Wistar yang 
dikelompokkan menjadi lima kelompok perlakuan, yaitu: kontrol, simvastatin (1,3 mL/270 g BB), kolesterol (lemak babi 9:1), VCO 1 (1 
mL/270 g BB), dan VCO 2 (1,3 mL/270 g BB). Perlakuan diberikan secara oral. Kadar kolesterol total, kadar LDL dan kadar HDL 
diukur pada hari ke-1, ke-14 dan hari ke-28. Data kadar kolesterol (kolesterol total, LDL dan HDL) dianalisis dengan ANCOVA dan 
dilanjutkan dengan uji contrast pada taraf signifikansi 5%. Hasil penelitian menunjukkan bahwa perlakuan VCO pada berbagai dosis 
berpengaruh nyata terhadap penurunan kadar kolesterol total darah, kadar LDL darah dan peningkatan kadar HDL darah tikus putih (R. 
norvegicus) hiperkolesterolemik. 
Kata kunci: kolesterol, aterosklerosis, VCO.  
INTRODUCTION 
Cardiovascular disease (CVD) is a degenerative disease 
that most often occur and becomes a major killer in 
industrialized countries. In Indonesia, the National 
Household Health Survey 1992 states, CVD became the 
first rank as the cause of death to people over 40 years of 
age. A major cardiovascular disease of the productive age 
is coronary heart disease (CHD), which is closely related to 
atherosclerosis (Kalim et al. 1996). Atherosclerosis is the 
hardening of the arteries caused by accumulation of 
cholesterol in the blood vessels due to the imbalance of 
influx - reflux of cholesterol (Prabowo et al. 1995). 
Hypercholesterolemia is a major risk factor for 
atherosclerosis that underlies the formation of CHD 
(Marinetti 1990; Wresdiyati 2006). The occurrence of CVD 
can be reduced by decreasing the formation of 
atherosclerosis by lowering cholesterol levels in the blood 
and increase the concentration of high density lipoprotein 
(High Density Lipoprotein/HDL) (Nogrady 1992). 
Early signs of atherosclerosis is the occurrence of injury 
on the blood vessel wall, especially endothelial followed by 
the deployment of lymphocytes and monocytes, 
macrophage formation, lipid deposition, smooth muscle 
proliferation and extracellular matrix synthesis. Various 
efforts to reduce levels of cholesterol in the blood can be 
performed using chemical drugs containing compounds or 
lipid-lowering agents as well as traditional medicine. 
Therapies with traditional medicine are perceived to be 
cheaper and the procedure is easier than synthetic chemical 
drugs. 
 Virgin Coconut Oil (VCO) or pure coconut oil is 
coconut oil produced from fresh coconut milk without 
heating or the addition of any materials. This virgin 
coconut oil contains 100% fat consisting of 92% saturated 
fatty acids, 6% monounsaturated fatty acids, and 2% 
polyunsaturated fatty acids. Saturated fatty acids in VCO 
consist of 90% medium-chain fatty acids and 10% long-
chain fatty acids. Medium-chain fatty acids in VCO are 
dominated by lauric acid (C12), namely 45-55%. In the 
body of saturated fatty acid, this medium chain is broken 
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and is being used to produce energy and is rarely stored as 
body fat or accumulates in the blood vessels. These fatty 
acids can be absorbed easily and quickly burned and used 
as energy for metabolism thus increasing metabolic 
activity, so it can help protecting the body from disease and 
accelerate healing (Enig 2001) 
Empirically VCO is known to be beneficial to health. 
Among others, VCO consumed each day can boost 
immunity, prevent disease caused by infection of bacteria, 
fungi and viruses, help to overcome obesity, prevent heart 
disease, atherosclerosis, and overcome cholesterol, diabetes 
and cancer.  
So far there has been no solid foundation and scientific 
evidence about the VCO potential as anti cholesterolemic 
and anti-atherosclerosis agent. Based on this fact, 
researchers want to know the effect of VCO on blood 
cholesterol levels of hypercholesterolemia white rats which 
is an early sign of atherosclerosis.  
MATERIALS AND METHODS 
Materials 
In this study, animals used were 25 of male white rats 
(Rattus norvegicus L.), Wistar strain, at age of 2 months 
with body weight of 250-290 g and were obtained from 
LP3HP-LPPT Gadjah Mada University, Yogyakarta. 
Virgin Coconut Oil was from the Integrated Coconut 
Processing Center of Yogyakarta. Lard was from LP3HP-
LPPT Yogyakarta. Simvastatin was a production of Kimia 
Farma. The food of test animal was pellets BR-II.  
Procedures 
Experimental animal. Before being used in the 
experiment, white rats were being adapted for 7 days in 
order to get used to the environment. Handling of 
experimental animals was in accordance with generally 
accepted protocol (Malole 1989). 
Simvastatin dose determination. The dose used for 
human hyper-cholesterolemia is 10 mg/day. Doses of 
simvastatin were converted to Rattus norvegicus L based 
on Laurence and Bacharach conversion table cited by 
Haznam (1976), and it gave result 10 mg/day x 0.018 = 
0.18 mg/day/200 g BW. Simvastatin suspension was 
obtained by dissolving 0.18 mg of simvastatin in the form 
of powder into 1 mL of distilled water. For rats weighing 
270 g, 1.3 mL suspension of simvastatin was required  
Determination of dosage and VCO delivery. VCO 
given to human therapy is 3 tablespoons or equal to 45 
mL/day (Dayrit 2000). When converted to rat, it was 0.018 
X 45 = 0.81 mL./200 g BW/day or equal to 1.09 mL/270 g 
BW/day. In this study, variations of dose was given, 
namely dose I = 1 mL/day/270 g BW and dose II = 1.3 
mL/day/270 g BW. 
Treatment of experimental animals. For 
measurement of blood cholesterol levels, this study used 25 
male rats (Rattus norvegicus L.), which were grouped into 
5 treatment groups, 5 mice for each, as follows: 
? Group I: treatment of distilled water and pellets for 28 
days (control) 
? Group II: treatment of pellets and lard with ratio 9:1 for 
14 days, then followed with Simvastatin until day 28th. 
? Group III: treatment of a mixture of pellets and lard 
with ratio 9 : 1 for 14 days, continued with pellets and 
distilled water until day 28th. 
? Group IV: treated with mixture of pellets and lard with 
ratio 9 : 1 for 14 days, followed by VCO treatment with 
dose of 1 mL until day 28th. 
? Group V: treated with mixture of pellets and lard with 
ratio 9 : 1 for 14 days, followed by VCO treatment with 
dose of 1.3 mL up to 28 days 
The provision of food and water was in ad libitum way, 
and VCO and Simvastatin treatment were given orally 
using a cannula needle. At the beginning of treatment and 
at the end of their treatment, weight loss of mice was 
weighed. 
Determination of blood cholesterol levels. Blood 
cholesterol levels are determined by Enzymatic Endpoint 
Method with a spectrophotometer (Kayamori et al. 1999). 
Blood was taken from the orbital sinus by microhematokrit, 
and then placed in a container, after that it was dripped 
with heparin as anti-coagulant on day 1st (after 
acclimation), on day 14th, and on day 28th. The 
measurement of blood cholesterol contents were to all 
cholesterol contents, namely HDL and LDL. The contents 
of HDL and LDL were measured with precipitation and 
enzymatic method. 
Data analysis 
Quantitative data (total cholesterol content, LDL 
cholesterol and HDL cholesterol) were analyzed by T 
dependent test to determine the effect of 10% of lard. 
While, data for treatment effect was analyzed by Ancova 
(Analysis co Variance), and when there were real 
differences, it continued by a contrast test at significance 
level of 5% to find out the differences among the 
treatments.  
RESULTS AND DISCUSSION 
This study used test animals of Wistar strain male white 
rat aged 2-3 months. Rats were used because it had 
similarities with humans in terms of physiology, anatomy, 
nutrition, pathology, and metabolism and were commonly 
used in research on cholesterol levels. Male rats are used 
because they are less affected by hormonal changes 
(Sitepoe 1992). According to Ganong (2002), estrogen 
effects blood cholesterol. In male rats, blood lipids are not 
affected with this estrogen because these animals have less 
estrogen.  
This research went through several stages namely 
acclimation of animals to adapt to the conditions of 
surrounding environment, providing high-cholesterol diet 
and its treatment with VCO. During acclimation, all rats 
were given pellets food and drinking water ad libitum for 7 
days. High-cholesterol diet by mixing the pellets food with 
lard at a ratio of 90:10 was given for 14 days. In VCO 
treatment, mice were given VCO for 14 consecutive days 
and use Simvastatin patented drug as the positive control. 
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Parameters observed in this study were the content of total 
blood cholesterol, LDL cholesterol, and HDL cholesterol.  
From the statistical tests, giving lard (ratio 9:1) in the 
food caused a significant increase (P <0.05) on total blood 
cholesterol level for as high as 10.7%, LDL levels 
increased by 55.52% and no significant decrease in levels 
of HDL cholesterol by 2.17%. This situation occurred due 
to increased accumulation of fat in the liver which resulted 
in an increasing number of acetil co-A in liver cells to 
produce cholesterol (Guyton 1991). Lard contains high 
saturated fatty acid. Triglicerida levels of saturated fat 
resulted in increased blood cholesterol and were a 
precursor. Consuming saturated fats may cause an increase 
of total cholesterol and a decrease of HDL thereby 
increasing the ratio of total cholesterol and HDL, so the 
risk of atherosclerosis is greater (Baraas 1993). Eating too 
much fat may cause hyperlipidemia with the increase of 
apo B cholesterol and LDL. The increase in apoB 
cholesterol is associated with the decrease in LDL receptor 
function (Verde et al. 1999). 
Blood total cholesterol level 
Cholesterol is present in all tissues and lipoproteins 
plasma. It exists in the form of free cholesterol or a 
combination of long chain fatty acids as esters kolestril. 
This element is synthesized from Acetil-co A and 
eventually expelled from the body through the bile as 
cholesterol salt. Free cholesterol is expelled from tissues by 
HDL and transported to the liver to be converted into bile 
acids (Murray et al. 1999). The state of 
Hypercholesterolemia is characterized by increased blood 
cholesterol levels above normal. In R. norvegicus Wistar 
strain rats, normal blood cholesterol level is 10-54 mg/dl 
(Smith and Mangkoewidjojo 1998).  
Results of analysis of blood cholesterol levels are 
presented in Table 1. Statistical tests, treatment with VCO 
and Simvastatin can reduce total blood cholesterol levels 
significantly. Giving VCO 1 mL per day for 14 days can 
reduce total cholesterol by 19.1% and 1.3 ml of VCO per 
day for 14 consecutive days can lower total cholesterol 
27.83%. Giving Simvastatin can reduce total cholesterol by 
28.8%. The most effective dose VCO for lowering total 
cholesterol levels in this study was 1.3 mL, not so 
significantly different to the giving of Simvastatin. 
In group I (control), rats were not fed with lard from the 
beginning to the end of treatment, at day 14th, they had 
decrease in levels of total cholesterol and at the end of 
treatment an increase of 4.6% occurred. Meanwhile in 
group III (cholesterol) that were given feed with lard up to 
day 14th and without being given lard until day 28th, a 
decline in total cholesterol level with 6.7% which was 
significantly different from those treated by VCO. 
 
 
Table 1. The mean of total blood cholesterol levels of white rats (R. norvegicus) (mg/dl) on day 1st, 14th and to 28th and the percentage 
of increase and decrease. 
  
Treatment 1st Day 14th Day Increase (%) 28th Day Decrease (%) 
Control 52.92+3.08 50.42+4.32 -4.7 52.74+4.17a  -4.6 
Simvastatin 52.84+1.65  60.44+2.56 14.38 42.98+4.78b 28.8 
Cholesterol 53+5.4 59.94+2.96 13.09 55.9+5.6a 6.74 
VCO 1 mL 51.7+0.96 58.84+2.9 13.8 47.6+2.8b 19.1 
VCO1,3 mL 52.81+4.55 61.8+6 17.4 44.6+2.76b 27.83 
Note: different letters in the same column indicate significant differences (P <0.05) 
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Figure 2. Total blood cholesterol levels of R. norvegicus. Note: The level of blood cholesterol (mg/dl) vs time (days): a. The control 
group, simvastatin, cholesterol, VCO 1 mL, 1.3 mL VCO. b. Control, c. Simvastatin, d. Cholesterol, e. VCO 1 mL, f. VCO 1.3 mL. 
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According to Shah (2005), the VCO has a saturated 
fatty acid content which is dominated by medium-chain 
fatty acids. Chain fatty acids are dominated by lauric acid. 
Because of the small molecular size, medium-chain fatty 
acids are easily absorbed through the intestine without 
enzymatic process. These fatty acids are carried to the liver 
blood flow to be metabolized and transported to the 
mitochondria without carnitine to produce energy quickly 
and efficiently so they are not deposited as fat in the tissue. 
The results are consistent with research conducted by 
Nevin (2004) on Sprague-Dawley rats animals fed diets 
VCO which showed that total cholesterol blood and LDL 
are decreased and HDL levels are increased. The increase 
and decrease in total cholesterol levels in blood during the 
experiment are shown in Figure 2. 
LDL blood 
Low Density Lipoprotein is a lipoprotein that transports 
lipids from the liver to the peripheral (extra-hepatic) and is 
often called "bad" cholesterol. According to Murray et al. 
(1996), LDL contains a half to two thirds of cholesterol. 
High levels of LDL are at risk of atherosclerosis. 
Results of analysis of blood LDL levels were presented 
in Table 2. Treatment with a VCO was capable of lowering 
blood LDL levels significantly. Giving VCO 1 mL per day 
for 14 consecutive days reduced LDL levels by 12.2% and 
1.3 ml of VCO per day for 14 days reduced LDL levels by 
28%. Giving VCO 1.3 mL was not significantly different 
from the provision of Simvastatin, which is 28%.   
Giving statins including simvastatin reduces blood LDL 
levels, inhibits HMG Co A reductase that would inhibit 
HMG Co A becoming into mevalonat so it inhibits 
cholesterol synthesis and cause a decrease in the 
concentration of cholesterol in the liver cells and increase 
the LDL receptor (E, Apo-B-100). 
In this study, giving Simvastatin causes LDL levels 
decreased from 26.5 at day 14th to 19.08 on day 28th. In 
group I (Control) which are not fed with lard, until the end 
of treatment there was a slight decrease at 1.7%. Group III 
during the first 14 days fed with lard and 14 days later no 
lard fed, there was an increase in blood LDL levels by 6%, 
this was possible because the addition of hepatic 
cholesterol also comes from foods that contain cholesterol, 
so cholesterol levels in the body will remain high because 
the body also produces cholesterol. In this study, the giving 
of VCO lowered blood LDL levels and total cholesterol of 
blood level. This occurs because 65% of them in the form 
of LDL cholesterol, so if total cholesterols are decreased 
the levels of LDL are also decreased. The increase and 
decrease in LDL levels in blood during the experiment can 
be shown in Figure 3. 
 
 
Table 2. The mean levels of LDL blood of white rat (Rattus norvegicus L) (mg/dl) on day 1st, to 14th and to 28th and the percentage of 
increase and decrease. 
 
Treatment 1st Day 14th Day Increase (%) 28th Day Decrease (%) 
Control 19.1+4.1 25.78+5.12 34.97 25.34+5.44a 1.7 
Simvastatin 17.84+3.16 26.5+3.53 48.54 19.08+4.02b 28 
Cholesterol 15.3+1.53 32.2+6.83. 110.45 34.14+7.11a 6.02 
VCO 1 mL 17.88+4.07 22.58+1.99 26.28 19.82+2.71b 12.22
VCO1,3 mL 15.96+4.66 26.82+4.88 68.04 19.3+1.8b 28 
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Figure 3. Blood levels of LDL R. norvegicus. Note: The level of blood LDL (mg/dl) vs time (days): a. The control group, simvastatin, 
cholesterol, VCO 1 mL, VCO 1.3 mL. b. Control, C. Simvastatin, d. Cholesterol, e. VCO 1 mL, f. VCO 1.3 mL. 
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HDL blood 
High Density Lipoprotein (HDL) cholesterol is often 
called "good" because it is a lipoprotein that transports 
lipids from the periphery to the liver. Because the 
molecules are relatively small compared to other 
lipoproteins, HDL can pass through the vascular 
endothelial cells and into the intima to bring back the 
accumulated cholesterol in macrophages, besides, the HDL 
also has antioxidant properties that can prevent the 
oxidation of LDL. The low levels of HDL in the blood will 
increase the risk of atherosclerosis and coronary heart 
disease (Moeliandari and Wijaya 2002). 
The results of Blood HDL analysis are presented in 
Table 3. From the statistical tests, the treatment with lard 
feeding for 14 days in different groups decreased HDL 
levels which were not significantly different. While at the 
end of treatment, increased HDL levels were significantly 
different. In group I (control), an increase levels of HDL 
cholesterol by 3.58% occured at the end of treatment. In 
group II (Simvastatin), an increase in HDL levels by 16%. 
This group had HDL levels that were not significantly 
different with the group given with 1.3 mL VCO. Group III 
(cholesterol) that are not fed with lard after day 14th, until 
the end of treatment on day 28th there was an increase in 
HDL cholesterol by 8% only. Groups of mice that have the 
highest HDL levels are group which was fed with 1 mL of 
VCO by 29.68 mg/dl, and they are not significantly 
different with the group given by 1.3 mL VCO for 29.6 
mg/dl. Giving VCO with two kinds of doses can raise 
levels of HDL better than giving Simvastatin. The decrease 
and increase of HDL levels in the blood are shown in 
Figure 4. 
Virgin coconut oil is coconut oil composed by medium-
chain fatty acids (C12), which are dominated by lauric 
acid. Medium-chain fatty acids (MCT) are more polar 
(faster in releasing H ions) than long-chain fatty acids 
(LCT). The nature of MCT solubility in water which is 
higher than LCT makes easier its entry into the liver 
directly via the portal vein after absorbed by the intestine 
without pancreatic lipase and rapidly metabolized into 
energy. Medium-chain fatty acids are not included in the 
cycle of cholesterol and do not accumulate as fat in body 
tissues. (Dayrit 2003). According to Enig (2001), lauric 
acid contained in the VCO is able to burn fat from other 
sources, and quickly made the energy and increase 
metabolism. In this study, the effect of VCO with its lauric 
acid content causes an increase in HDL levels. The 
function of HDL is to transport cholesterol from peripheral 
tissues to the liver, removing excess cholesterol and 
inhibits the development of atheroma plaque, so the 
increase in HDL levels in the blood will prevent the risk of 
atherosclerosis. 
 
 
Table 3. The mean levels of blood HDL (mg/dl) of white rat (R. norvegicus) on day 1, to 14 and to 28 and percentage changes. 
 
Treatment 1st Day 14th Day Increase (%) 28th Day Decrease (%) 
Control 21.38+1.94 23.98+4.74 -0.12 24.84+2.8b 3.58 
Simvastatin 25.26+ 23.44+2.58 7.2 27.18+3.68a  16  
Cholesterol 21.32+1.95 19.94+3.19 6.47 21.58+2.28b 15.95 
VCO 1 mL 23.98+4.74 22.26+2.19 7.17 29.68+4.75a  33.3 
VCO1,3 mL 23.2+2.93 22.68+ 2.24 27.6+3.43a  21.69 
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Figure 4. Blood levels of HDL R. norvegicus. Note: The level of blood LDL (mg/dl) vs time (days): a. The control group, simvastatin, 
cholesterol, VCO 1 mL, 1.3 mL VCO. b. Control, c. Simvastatin, d. Cholesterol, e. VCO 1 mL, f. VCO 1.3 mL. 
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Virgin Coconut Oil (VCO) is coconut oil which 
contains 92% saturated fatty acids that are dominated by 
medium-chain fatty acids (MCT), which is 44% -55% are 
lauric acid. MCT metabolism is different from long chain 
fatty acids (LCT), MCT can be absorbed rapidly in the 
intestinum without the need for pancreatic lipase, and 
carried by the portal vein into the liver and rapidly oxidized 
into energy. This energy is used to increase metabolism, 
which can help protect the body from disease and 
accelerate healing. 
According to Carandang (2005), VCO also contains an 
active ingredient, although in small amounts that can 
prevent and provide protection against disease and is 
beneficial to health. The active ingredient is known as 
tocopherol, an antioxidant that has a phyti saturated side 
chain, and tocotrienols, a better antioxidant than tocopherol 
with unsaturated isoprenoid side chain with three double 
bonds. Both of these active ingredients have a 
hypocholesterolemic effect, anti-atherogenic and anti 
cancer. Its anti-atherogenic activity is by inhibiting the 
oxidation of LDL, suppresses the activity of HMG-Co A 
reductase and inhibits platelet aggregation (Theriault et al. 
1999 in Carandang 2005). This is similar to the mechanism 
of simvastatin in lowering cholesterol levels and reduces 
levels of LDL. Other active ingredients in the VCO are 
flafonoid and polyphenols. Flavonoids as antioxidants have 
good effects on endothelial function namely reducing the 
oxidation of LDL and increasing the production of Nitric 
Oxide (NO) (Vita 2005). The oxidation of LDL would 
induce inflammatory responses by producing leukocyte and 
cytokine on endothelial. Flavonoids reduce LDL oxidation 
and prevent inflammation in indotel. Nitric Oxide is an 
endogenous vasodilator that has the ability of anti-
atherosclerosis. Polyphenols will prevent the oxidation of 
LDL. Oxidation of LDL would generate Reactive Oxygen 
Species (ROS) that are toxic, and if it binds with NO, it 
forms peroxynitrite oxidant. Oxidation of cholesterol is to 
spur the process of atherosclerosis.  
In this study, measurement of total cholesterol and LDL 
levels in both treatment doses showed a decrease, but not 
significantly different from simvastatin treatment. Decrease 
in cholesterol levels will reduce the occurrence of 
atherosclerosis. 
CONCLUSION 
Giving VCO (Virgin Coconut Oil) on hypercholeste-
rolemic white rats (Rattus norvegicus L.) leads to lower 
cholesterol levels (total cholesterol, LDL) and HDL levels 
at a significance level of 5%, not so significantly different 
from the provision of patented drug Simvastatin as 
cholesterol-lowering drugs.  
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